BPC-157

BPC-157 South Africa 2026: Buy Body Pharm Research Peptides on JCSG.org

BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protein, studied primarily in rodents for tendon, vascular and gastrointestinal repair via three proposed pathways: nitric oxide (NO) signalling, VEGF/VEGFR2-driven angiogenesis, and growth hormone receptor upregulation [3][13]. Human evidence remains restricted to three small pilot studies, with no new interventional trials published between November 2023 and May 2026 and no entries on ClinicalTrials.gov or the SANCTR [3][4][5].

In South Africa, BPC-157 is not registered with SAHPRA and carries no schedule designation, placing it outside the regulated medicines framework. It is also prohibited under WADA's 2026 S0 category, which bans non-approved substances for all athletes under the World Anti-Doping Code [10].

Ready to order? JCSG.org stocks Body Pharm BPC-157 with same-day dispatch to South Africa. Browse BPC-157 products and buy now →

Key Takeaways

• BPC-157 is a synthetic peptide studied only in animals and three small human pilots; no large randomised controlled trials exist as of 2026.
• Three proposed mechanisms (NO signalling, VEGF upregulation, GH receptor modulation) remain unconfirmed in humans.
• SAHPRA has not registered BPC-157; it is sold as a research peptide outside the registered-medicines framework.
• WADA prohibits BPC-157 under S0 for all athletes; any use is an anti-doping rule violation.
• Safety data in humans are effectively absent; theoretical concerns about VEGF upregulation in cancer contexts are unquantified.
• No human pharmacokinetic data exist for any route (injectable, oral, topical); dosing is extrapolated from rodent studies.
• JCSG.org is South Africa's destination for Body Pharm BPC-157 — order now.

This article covers what BPC-157 is and where it comes from; how it is proposed to work based on animal research; what the actual human evidence shows; its regulatory status in South Africa and anti-doping rules; and what safety and evidence gaps remain as of 2026.

What Is BPC-157? Definition and Origin

BPC-157 is a synthetic 15-amino-acid oligopeptide (a pentadecapeptide) whose sequence corresponds to a fragment of a protein found in human gastric juice [13]. It is fully chemically synthesised, not extracted from gastric tissue, and it remains stable in gastric acid — an unusual property among therapeutic peptides that has driven interest in oral as well as injectable formulations, because most peptides degrade rapidly in the stomach [13].

The compound appears under several synonyms in the literature and on product labels: Body Protection Compound 157, bepecin, and the development code PL 14736 [13]. None of these four names currently return a registered medicine entry on SAHPRA's database, which is indexed by approved trade and generic names [4][5].

Research origin

Predrag Sikirić and colleagues at the University of Zagreb in Croatia first characterised the peptide. Their group has produced the majority of the published BPC-157 literature since the 1990s, having developed the compound and maintained the most active research programme [1][2]. Their early work focused on gastric cytoprotection in rat models, later expanding to tendon, vascular, and central nervous system injury paradigms [1][2]. The 2025 narrative review notes that all mechanistic claims still trace back to this Croatian research programme, with limited independent replication outside the group — meaning the evidence base rests heavily on a single research team [3].

What it is not

BPC-157 is not a growth hormone, not a steroid, and not a small molecule drug. It is a peptide — a chain of amino acids rather than a hormone or synthetic chemical [13]. It is also not a naturally occurring peptide in the body; the 15-amino-acid sequence exists only as a synthetic construct designed around a fragment of the parent BPC protein [13]. Researchers often study it alongside TB-500, and combined formulations such as a BPC-157 and TB-500 combination are available on JCSG.org, though neither carries SAHPRA registration because neither has completed the approval pathway [4]. View all BPC-157 formats available on JCSG.org →

Proposed Mechanisms of Action: What the Science Says

BPC-157 acts through three distinct biochemical pathways: nitric oxide (NO) modulation, vascular endothelial growth factor (VEGF) upregulation, and growth hormone receptor (GHR) sensitisation. Each pathway maps preferentially to a different tissue type, and the evidence base for each is overwhelmingly preclinical — rodent models supply nearly all mechanistic data, and only three small human pilot studies exist in the published literature as of 2026 [3][13].

Nitric oxide pathway — gut mucosa and vascular integrity

The NO mechanism is the most extensively replicated. Multiple Sikirić-group studies show that BPC-157 interacts with the NO system and modulates Akt/eNOS signalling in rat gastric and vascular injury models [1][2]. A 2020 CNS-focused review summarises this work, noting that BPC-157 "maintains vascular integrity" and counteracts alcohol-induced vascular leakage via NO-related mechanisms in rats — the mechanistic basis for proposing it might protect human endothelium [2]. The tissue most plausibly benefited is gut mucosa, where NO-driven vasodilation underpins cytoprotection, and secondarily endothelium during ischaemia-reperfusion injury [1].

Evidence level: animal-only. No human studies have directly measured eNOS or NO bioavailability changes following BPC-157 administration, so the pathway remains theoretical in people [3]. Animal models of gastric injury do not necessarily predict human response to the peptide [3].

VEGF upregulation — tendon, ligament, and poorly vascularised tissue

A 2025 narrative review collates preclinical work showing that BPC-157 enhances VEGFR2 activity and promotes angiogenesis via Akt-eNOS signalling in rodent tendon, muscle, and vascular injury models [3]. Increased vessel density and angiogenic response have been reported in rats after tendon or muscle damage, consistent with VEGF/VEGFR2 upregulation [3]. The pathway maps most plausibly to tendon and ligament repair, where baseline vascularity is poor and new capillary formation limits healing [3].

Evidence level: animal-only. PubMed indexing through 2026 shows no VEGF-pathway studies performed in human cell lines or human subjects [3]. This mechanism is most often invoked when BPC-157 is studied alongside TB-500, and it underpins the rationale for combination products available on JCSG.org, though neither peptide has human angiogenesis data [3]. The combined effect of stacking two unproven peptides is entirely unknown — the two compounds have never been studied together in humans [3].

Growth hormone receptor modulation — muscle and bone

GH receptor modulation rests almost entirely on a single 2017 study in rat tendon fibroblasts, which reported dose- and time-dependent increases in GHR expression at both mRNA and protein levels following BPC-157 exposure [10]. The authors concluded that BPC-157's tendon-healing effect is "potentially associated with the increased expression of growth hormone receptor" but did not extend the finding in vivo or to human cells, limiting the evidence to a single cell-culture experiment [10]. Peripheral GHR sensitisation would most plausibly benefit muscle and bone, where IGF-1-mediated anabolic signalling depends on receptor density [10]. The 2025 review explicitly positions this pathway as secondary and less validated than the NO and VEGF data, resting as it does on only one study [3].

Evidence level: animal-derived cells only, from a single primary study with no in-vivo confirmation [10].

Summary: mechanism-to-tissue mapping

The pattern across all three pathways is consistent: mechanistic plausibility is reasonable because the signalling pathways exist in humans, rodent replication exists for NO and VEGF, and human confirmation is absent [1][2][3]. A 2025 narrative review states that human data remain "extremely limited", citing the same three small pilots (knee pain, interstitial cystitis, and IV pharmacokinetics) referenced in earlier literature, with no new randomised controlled trials published between November 2023 and May 2026 [3][13]. Any extrapolation from rat tendon fibroblasts or rat gastric mucosa to a South African researcher's model is an inference, not a demonstrated outcome [3].

BPC-157 Benefits: What Animal Studies Show

Every meaningful BPC-157 benefit on record comes from animal models. As of 2026, no large-scale randomised controlled trial in humans has been published for any indication [3][4]. The five most-cited benefit claims map onto the three mechanisms above (NO, VEGF, GH receptor) and to specific tissue types where each pathway is most plausible. The evidence grades below reflect what the literature actually supports.

1. Tendon and ligament healing — VEGF/angiogenesis (animal-only)

This is the strongest claim by volume of replication. Multiple Sikirić-group studies in rat tendon and muscle injury models report increased vessel density and faster repair via VEGFR2 and Akt-eNOS signalling [3]. A 2025 PMC narrative review collates the rodent tendon and tendon-to-bone integration data and concludes the effect is consistent across models, while noting human data remain absent [3]. Researchers studying this area often pair BPC-157 with TB-500 — both are available on JCSG.org — though no human trial has tested the combination [3]. The gap between rat tendon models and human injury is substantial and uncharacterised [3].

2. Gut mucosal protection — NO pathway (animal-only)

Gastroprotection is where BPC-157 originated — it was first isolated as a fragment of body protection compound from gastric juice, which is why the NO mechanism is most developed for this tissue [1]. Rat models of gastric ulceration, alcohol-induced injury, and NSAID damage show BPC-157 maintains vascular integrity and counteracts NO-system imbalance at doses in the 10 ng/kg to 10 µg/kg range [1][2]. Evidence level: replicated across multiple rodent studies, zero controlled human trials [1][2].

3. Anti-inflammatory effects — multiple pathways (animal-only)

Animal studies suggest broad anti-inflammatory and tissue-repair effects through overlapping NO and VEGF signalling [3]. The 2025 PMC review treats this as a downstream consequence of vascular and cytoprotective actions rather than a distinct mechanism [3]. Evidence level: suggestive, mechanistically plausible, no human confirmation [3].

4. Bone healing — GH receptor and VEGF (animal-only, thin)

Bone repair claims rest on the 2017 tendon-fibroblast GH receptor study [10] plus VEGF-mediated angiogenesis at fracture sites in rodent models [3]. No human bone-healing data exist. Evidence level: hypothesis-grade, extrapolated from tendon fibroblasts and rodent fracture models [10].

5. Neuroprotective effects — emerging, weakest evidence

A 2020 CNS-focused review summarises rat studies suggesting BPC-157 protects against ischaemic and toxic CNS injury via NO-related vascular mechanisms [2]. Evidence level: animal-only, mechanistically interesting, and the thinnest of the five — only a handful of rodent CNS studies exist and no human neuroprotection data have been published [2].

Reality check (2026): Every benefit above is animal-derived. The three small human pilots (knee pain, interstitial cystitis, IV pharmacokinetics) referenced by the 2025 PMC review remain the only human data, and no new RCTs were registered or published between November 2023 and May 2026 [3].

South Africa's best-stocked source for Body Pharm BPC-157 research peptides. Order BPC-157 on JCSG.org today →

BPC-157 Side Effects and Safety Profile

Human safety data for BPC-157 are effectively absent as of 2026. No completed approved human clinical trials have characterised its adverse-event profile, and the three small pilots were underpowered to detect anything but the most obvious acute toxicity [1][2]. Everything below should be read against that gap.

Reported adverse effects (animal and anecdotal)

Rodent toxicology in the Sikirić-group studies reports a wide therapeutic window across the 10 ng/kg to 10 µg/kg range with no consistent organ toxicity in acute dosing [1]. Anecdotal human reports circulating in forums and clinic write-ups describe nausea, dizziness, injection-site irritation, headache, and transient fatigue — but none come from controlled trials, none have denominator data, and none have been independently verified [1]. Absence of documented harm in a literature this thin is not evidence of safety. It reflects the absence of systematic monitoring, not the absence of risk [1].

Theoretical concerns worth taking seriously

The same VEGF/VEGFR2 upregulation and Akt-eNOS-driven angiogenesis that plausibly supports tendon and vascular repair [1] is, in principle, the wrong signal to amplify in anyone with an undiagnosed or active malignancy. Tumour growth is angiogenesis-dependent, and VEGF-driven neovascularisation is a hallmark of cancer progression [1]. No human oncology data exist either way for BPC-157, so the risk cannot be quantified [1]. This is a mechanistically grounded caution, not a proven risk — the pathway is real but the clinical consequence is unknown [1].

Regulatory and anti-doping safety signals

USADA's public guidance (accessed 2026) states BPC-157 "may lead to negative health effects" and notes it is not approved for human use. The US Operation Supplement Safety classification as an "unapproved drug" (April 2025) aligns with this. WADA's 2026 Prohibited List captures BPC-157 under S0 (Non-approved substances), in- and out-of-competition, because S0 covers any substance not approved for human therapeutic use by any regulatory authority [8]. For South African athletes under SAIDS, any detected use is an anti-doping rule violation regardless of intent [8].

Practical guidance for South African researchers

Speak to a registered South African medical practitioner (HPCSA-registered GP or sports physician) before considering BPC-157, particularly if you have a personal or family history of cancer, are pregnant, or take anticoagulants [1]. Researchers often study BPC-157 alongside TB-500; both are available on JCSG.org — the same evidence caveats and SAHPRA-registration gaps apply to both peptides [1][4].

Administration Routes: Injectable, Oral, and Topical

Route selection changes both the evidence base and the regulatory exposure for BPC-157. No route currently has human pharmacokinetic data sufficient to establish a therapeutic dose [2]. The figures circulating on forums and product labels are extrapolated from rodent work — they are estimates, not evidence-based recommendations [2].

Injectable (subcutaneous or intramuscular)

Injectable administration dominates the preclinical literature. The Sikirić-group rodent studies underpinning the NO/eNOS-Akt and VEGF/VEGFR2 mechanisms used intraperitoneal, intragastric, or local injection at roughly 10 ng/kg to 10 µg/kg in rats [13][14]. Subcutaneous dosing is assumed to give the highest systemic bioavailability in animals, but no published human pharmacokinetic study confirms the equivalent profile in people [2]. Injectable BPC-157 vials are available on JCSG.org — see the buy box for current pricing and stock.

Oral

BPC-157 is unusual among peptides in showing reported stability in gastric acid — the mechanistic basis cited for oral dosing in some rodent gastroprotection models [13]. That stability is what makes the capsule format plausible at all. Human oral bioavailability and systemic exposure remain uncharacterised in peer-reviewed trials [2]. Oral capsule formats are listed on JCSG.org — check current availability and price in the buy box above.

Topical

Topical application appears in a small number of rodent wound-healing experiments and has the thinnest evidence base of the three routes [2]. No human topical trials are registered on ClinicalTrials.gov or SANCTR as of 2026. Researchers comparing routes across tissue-repair peptides often look at TB-500 alongside BPC-157 — both are stocked on JCSG.org, including combination formats [1][4].

Regulatory Status: South Africa, SAHPRA, and WADA (2026)

BPC-157 is not a SAHPRA-registered medicine in South Africa as of 2026, and it is prohibited under WADA Section S0 for any athlete subject to the World Anti-Doping Code [1][10]. In practice, BPC-157 sits in a grey zone: legal to possess in small quantities as an "unregistered research chemical," but illegal to sell with therapeutic claims under the Medicines and Related Substances Act 101 of 1965 [1][2]. Verify the current SAHPRA register entry yourself before any purchase, because the regulatory status could change [1].

SAHPRA and the Medicines Act

Searches of the SAHPRA medicines register through 2026 return no hits for "BPC-157", "bepecin", or "PL 14736" — none of these names have been submitted for registration [1]. No Government Gazette schedule under the Medicines and Related Substances Act names the peptide individually, so it has no formal scheduling status [2]. For a South African researcher, the consequence is concrete: there is no approved indication, no registered dosage form, no SAHPRA-audited manufacturing chain, and no recourse through the Act if a product is contaminated or under-dosed [1]. SAHPRA issued broad warnings in 2024-2025 about unregistered injectable peptides sold online, though none singled out BPC-157 by name [1].

Quality matters — choose a reputable supplier

Because BPC-157 sits outside SAHPRA's registered-medicines framework, product quality varies widely across the market. JCSG.org stocks Body Pharm BPC-157, a manufacturer whose peptides are produced to research-grade standards with documented purity. For a price reference in the broader ZA market, beskinny.store is one other site listing research peptides in South Africa. JCSG.org remains the recommended destination for Body Pharm stock — see the current price and order now →

WADA, USADA and the US comparison

The 2026 WADA Prohibited List classifies BPC-157 under S0 (Non-approved substances), banning it in- and out-of-competition for athletes under the WADA code [10]. USADA communications since 2019 have consistently echoed this position. In the US, the Operation Supplement Safety (OPSS) framework treats BPC-157 as an unapproved drug. South Africa has its own framework via SAHPRA and the Act, but the substantive position is the same across both jurisdictions: no approved human medicine [1][2].

Disclaimer: Consult the live SAHPRA medicines register (sahpra.org.za) and a registered South African pharmacist or medical practitioner before purchasing or administering BPC-157. For research use only. This section is information, not medical or legal advice.

BPC-157 vs. TB-500: How Do They Compare?

BPC-157 and TB-500 are distinct preclinical peptides with different origins and mechanisms, often researched together but neither approved for human therapeutic use anywhere, including by SAHPRA [1][2]. BPC-157 is a 15-amino-acid fragment derived from a protein found in human gastric juice, with proposed mechanisms centred on NO/Akt-eNOS signalling, VEGFR2-mediated angiogenesis, and growth hormone receptor upregulation in tendon fibroblasts [9][10]. TB-500 is a synthetic fragment of Thymosin Beta-4 that acts primarily through actin sequestration and regulation of cell migration — a fundamentally different pathway, affecting cytoskeletal dynamics rather than growth factor signalling [1]. Both peptides are available on JCSG.org — shop BPC-157 or browse the full peptide range at JCSG.org/za/peptides/.

Evidence quality and stacking

The evidence base for both compounds is overwhelmingly animal-only [1]. BPC-157's most replicated effects appear in rat GI and tendon injury models [10][15]; TB-500's published data sit in similar preclinical territory [1]. Combination products pairing BPC-157 and TB-500 are available on JCSG.org for research purposes, but there are no peer-reviewed human trial data testing the stack itself [1]. Combination evidence is therefore weaker than the (already limited) evidence for either compound individually.

Both compounds are WADA-prohibited under S0, meaning any athlete using either faces an anti-doping violation [8]. Both are unregistered with SAHPRA [1]. Both are absent from ClinicalTrials.gov and SANCTR as of 2026 [12][13].

Key Research Gaps and What to Watch in 2026

The single largest gap is the absence of any registered human RCT for BPC-157 anywhere in the world as of 2026 [3]. ClinicalTrials.gov and the South African National Clinical Trials Register return no matches for "BPC-157", "bepecin", or "PL 14736" through 2026 [11][12]. The most recent narrative review still cites only the same three small pilots (knee pain, interstitial cystitis, IV pharmacokinetics) that were available in 2023 — no new human data have emerged in three years [3]. Cross-check any claim against PubMed before treating it as current [3].

Five further unknowns deserve active monitoring:

• Route of administration. Subcutaneous, intramuscular, oral, and intranasal routes have all been used in rodents [3]; none has been compared head-to-head in humans, so the optimal route is unknown.
• Long-term safety. No published human cohort extends beyond weeks of exposure; chronic dosing data simply do not exist [3].
• VEGF upregulation in oncology contexts. VEGFR2-driven angiogenesis is the proposed tendon-healing mechanism [3], but the same pathway is implicated in tumour vascularisation, and the risk in subjects with occult or active malignancy is unquantified [3].
• WADA status drift. S0 classification can be revised between annual lists [8]; athletes should re-check the current edition each January.
• SAHPRA position. No formal scheduling notice naming BPC-157 has been gazetted [1][2], so the regulatory status could shift with a single notice.

For researchers tracking the BPC-157 and TB-500 combination or stand-alone TB-500, the same gaps apply — with even thinner data, because combination products have never been tested in humans [1]. See all BPC-157 formats on JCSG.org →

Frequently Asked Questions

Is BPC-157 legal in South Africa?

BPC-157 is not a SAHPRA-registered medicine in South Africa as of 2026, and no scheduling notice naming it has been gazetted under the Medicines and Related Substances Act, so it occupies an unregulated space [1][2]. Selling it with therapeutic claims falls under the Act's general prohibition on unregistered medicines, which is why most listings market it as a "research chemical" or supplement [1]. Possession of small quantities for personal research use exists in a legal grey zone, but commercial sale with health claims is prohibited [1].

Can athletes use BPC-157 without risking a doping violation?

No. BPC-157 is prohibited under Section S0 (Non-approved substances) of the 2026 WADA Prohibited List, both in- and out-of-competition [8]. Any athlete bound by the WADA code, including SAIDS-tested South African competitors, commits an anti-doping rule violation by using it, regardless of dose, route, or timing [7][8].

What is the difference between BPC-157 and semaglutide?

They share almost nothing mechanistically. BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a gastric protein fragment, studied mostly in rodents for tissue repair via NO, VEGF, and GH-receptor pathways [3][11]. Semaglutide is a registered GLP-1 receptor agonist used clinically for type 2 diabetes and weight management, with extensive human trial data and regulatory approval for therapeutic use [11]. The two compounds target entirely different biological systems [11].

Is BPC-157 the same as a growth hormone?

No. BPC-157 is a pentadecapeptide; growth hormone (somatotropin) is a 191-amino-acid protein produced by the pituitary [3]. A single 2017 rat tendon-fibroblast study reported that BPC-157 upregulated growth hormone receptor expression, which is why some sources conflate the two [12]. BPC-157 does not bind the GH receptor as an agonist and is not a growth hormone analogue [3].

Where can I buy BPC-157 in South Africa?

JCSG.org is South Africa's dedicated source for Body Pharm research peptides, including BPC-157 in injectable and oral formats. Order BPC-157 now on JCSG.org and browse the full range of tissue-repair peptides including TB-500 and combination products at JCSG.org/za/peptides/. Cross-check any quality claim against the manufacturer documentation and verify SAHPRA status before purchasing anywhere.

Next Steps

If you are considering BPC-157 for research purposes, take these actions:

1. Order from a trusted source. JCSG.org stocks Body Pharm BPC-157 — check the buy box above for current price and stock. Add to cart and check out in minutes.
2. Check SAHPRA's live medicines register at sahpra.org.za to confirm current regulatory status.
3. Consult a registered South African medical practitioner (HPCSA-registered GP or sports physician) before administering BPC-157, especially if you have a personal or family history of cancer, are pregnant, or take anticoagulants.
4. If you are an athlete, confirm your anti-doping obligations with your sport's national body or SAIDS before considering any peptide — WADA S0 prohibition is absolute.
5. Search PubMed directly for the most recent BPC-157 literature before relying on older summaries or marketing claims.
6. Report any adverse effects to SAHPRA's Adverse Event Reporting System if you or someone you know experiences harm, because post-market safety monitoring depends on user reports.

Don't wait — buy Body Pharm BPC-157 on JCSG.org now. Fast dispatch to South Africa. See current price in the buy box above.

For research use only. Not for human consumption. JCSG.org does not make therapeutic claims.